Company: AZN
Filing Date: 2025-09-17
Form Type: 6-K
Source: 0001654954-25-010847
Chunk: 6

Company: ASTRAZENECA PLC
Filing Date: 2025-09-17
Form: 6-K
Chunk 6
---
us: results from the systemic lupus international collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2015;74:1706-1713

19. The Rheumatologist. SLE Is a leading cause of death among women. Available at: https://www.the-rheumatologist.org/article/sle-is-a-leading-cause-of-death-among-women. [Last accessed: September 2025.]

20. Morand EF, et al. Advances in the management of systemic lupus erythematosus. BMJ 2023;383:073980.

21. Murimi-Worstell IB, et al. Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis. BMJ Open. 2020;10:e031850.

22. Riggs JM, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261

23. Katsumata Y et al. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study. Ann Rheum Dis. 2024;83:998-1005.

24. Lauwerys BR, et al. Type I interferon blockade in systemic lupus erythematosus: where do we stand? Rheumatol. 2014;53:1369-1376.

25. Sarkar MK, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018;77:1653-1664.

26. Jefferies CA. Regulating IRFs in IFN Driven Disease. Front Immunol . 2019;10:325.

27. Mai L, et al . The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. Arthritis Res Ther . 2021;23:29.

28. López de Padilla CM, et al . The Type I Interferons: Basic Concepts and Clinical Relevance in Immune-mediated Inflammatory Diseases. Gene . 2016;576(101):14-21.

29. Rönn